Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178120 | 0.79 | PIK3CD (0.47) | PIK3CDCYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL6985518 | 0.78 | PIK3CD (0.50) | PIK3CDJAK2TYK2 | |
| SCHEMBL1313527 | 0.77 | PIK3CD (0.49) | PIK3CD | |
| SCHEMBL4178087 | 0.75 | DPP4 (0.51) | PIK3CDALDH1A1 | |
| SCHEMBL10251465 | 0.75 | PIK3CD (0.50) | PIK3CDALOX15 | |
| SCHEMBL1312808 | 0.74 | PIK3CD (0.48) | PIK3CDCYP1A2CYP3A4TSHRCLK4 | |
| SCHEMBL1314085 | 0.74 | PIK3CD (0.51) | PIK3CDKMT2AALDH1A1 | |
| SCHEMBL4185246 | 0.73 | PIK3CD (0.50) | PIK3CDCYP3A4TSHRMEN1KMT2A | |
| SCHEMBL4181390 | 0.72 | PIK3CD (0.52) | PIK3CDCYP1A2CYP3A4TSHRCLK4 | |
| SCHEMBL4167563 | 0.72 | PIK3CD (0.49) | PIK3CDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139882-B1 | 3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | AMGEN INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8329910-B2 | Quinolines for the treatment of PI3K-δ mediated diseases | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329910-B2 | Quinolines for the treatment of PI3K-δ mediated diseases | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329910-B2 | Quinolines for the treatment of PI3K-δ mediated diseases | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8183258-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183258-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183258-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183259-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183259-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110281897-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100179177-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7705018-B2 | Substituted quinolines and their uses in treatment of inflammatory and related conditions | AMGEN INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705018-B2 | Substituted quinolines and their uses in treatment of inflammatory and related conditions | AMGEN INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705018-B2 | Substituted quinolines and their uses in treatment of inflammatory and related conditions | AMGEN INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-2139882-A1 | 3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS | Amgen Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20090023761-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023761-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023761-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2008118455-A1 | δ3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118455-A1 | δ3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023761-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PIK3CD 16/4885CYP1A2 2390/4885CYP3A4 3267/4885 |
| US-20100179177-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885CYP1A2 2390/4885CYP3A4 3267/4885 |
| US-20110281897-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 15/4885CYP1A2 2339/4885CYP3A4 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.